ArticleNPJ digital medicine2026
Multimodal multi-instance learning for cardiopulmonary exercise testing performance prediction.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a progressive and fatal disease that affects nearly 7 million individuals in the United States, with prevalence expected to surpass 10 million by 2040. Cardiopulmonary exercise testing (CPET) represents the gold standard for assessing functional capacity and predicting survival outcomes among HF patients but its widespread use is limited by practical constraints. Here we introduce a multimodal multi-instance learning framework that predicts peak oxygen consumption (peak VO₂), a critical indicator from CPET, using the more accessible transthoracic echocardiography (TTE) studies and electronic health records (EHR). By modeling the cross-modal interactions and the multi-instance structure of TTE studies, our approach significantly improves predictive accuracy and generalization. The model achieves an R² of 0.603 in peak VO₂ prediction and AUROC of 0.849 in high-risk patient identification, surpassing prior work (R² = 0.529, AUROC = 0.836). On the external validation cohort, the model achieves an R² of 0.541 compared to 0.395 and an AUROC of 0.870 compared to 0.797 from previous work. The improved performance more accurately allows for identification of patients who may benefit from advanced heart failure therapies that otherwise may have been missed.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.